Bazarko Daniel 4
4 · ALEXION PHARMACEUTICALS, INC. · Filed Jul 23, 2021
Insider Transaction Report
Form 4
Bazarko Daniel
SVP, Controller, CAO
Transactions
- Disposition to Issuer
Option to Purchase Common Stock
2021-07-21$176.80/sh−5,111$903,625→ 0 totalExercise: $176.80From: 2014-02-28Exp: 2024-02-28→ Common Stock (5,111 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2021-07-21$131.25/sh−5,300$695,625→ 0 totalExercise: $131.25From: 2017-02-28Exp: 2027-02-28→ Common Stock (5,300 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2021-07-21$180.28/sh−2,912$524,975→ 0 totalExercise: $180.28From: 2015-12-01Exp: 2025-12-01→ Common Stock (2,912 underlying) - Disposition to Issuer
Common Stock, par value $.0001 per share
2021-07-21−60,207→ 0 total - Disposition to Issuer
Option to Purchase Common Stock
2021-07-21$180.37/sh−3,943$711,199→ 0 totalExercise: $180.37From: 2015-02-27Exp: 2025-02-27→ Common Stock (3,943 underlying)
Footnotes (2)
- [F1]Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").
- [F2]Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.